Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T14:12:05.362Z.
Calculation as of: 2026-10-06T14:12:05.362Z.
Quote observation: 2026-10-06T14:10:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8ce36116f6c4cf8d6fa5d70ec9ce1d9cbc86489a03ebd5e18b87b9f8ced35068
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$1.50B
EV/EBIT Ratio
91.95x
TTM Avg
402.45x
3Y Avg
215.28x
5Y Avg
215.28x
Market Cap
$1.47B
EV/EBIT Ratio
10.09x
TTM Avg
25.95x
3Y Avg
23.59x
5Y Avg
24.10x
Market Cap
$1.45B
EV/EBIT Ratio
N/A
TTM Avg
5.99x
3Y Avg
5.99x
5Y Avg
5.99x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GH Research PLC (GHRS) | $1.49B | N/A | N/A | N/A | N/A |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.50B | 91.95x | 402.45x | 215.28x | 215.28x |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.47B | 10.09x | 25.95x | 23.59x | 24.10x |
| Braveheart Bio, Inc. (BRVE)vs › | $1.45B | N/A | N/A | N/A | N/A |
| Innoviva, Inc. (INVA)vs › | $1.53B | 7.58x | 117.97x | 74.38x | 44.05x |
| Certara, Inc. (CERT)vs › | $1.52B | 214.81x | 79.44x | 108.81x | 130.77x |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.45B | N/A | 5.99x | 5.99x | 5.99x |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 11.61x | 36.76x | 36.76x | 36.50x |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.40B | N/A | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.35B | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
